Erschienen in:
18.03.2022 | Original Article
The acute, systemic effects of aerobic exercise in recently concussed adolescent student-athletes: preliminary findings
verfasst von:
P. R. Worts, J. R. Mason, S. O. Burkhart, M. A. Sanchez-Gonzalez, J-S. Kim
Erschienen in:
European Journal of Applied Physiology
|
Ausgabe 6/2022
Einloggen, um Zugang zu erhalten
Abstract
Objectives
Examine the acute effects (pre-, during, post-intervention) of two different intensities of aerobic exercise or rest on autonomic, oculomotor, and vestibular function and symptom burden in patients with a recent sport-related concussion (SRC) and compare their responses to sex-matched, age-stratified, non-concussed (HEALTHY) student-athletes.
Methods
Student-athletes between the ages of 13 and 18 that presented to the sports medicine clinic within Day 3–7 post-SRC and from local schools were recruited for a randomized controlled trial (RCT). The participants were administered the Vestibular/Ocular Motor Screening (VOMS), King-Devick (K-D), and Post-Concussion Symptom Scale (PCSS) before and after the intervention. Heart rate variability (HRV) and mean arterial pressure (MAP) were collected before, during, and after the intervention. The intervention was either a single, 20-min session of treadmill walking at 40% (40HR) or 60% of age-predicted max heart rate (60HR), or seated, rest (NOEX).
Results
30 participants completed the intervention with the SRC group treated 4.5 ± 1.3 days post-injury. Pre-exercise HRV and MAP were significantly different (p’s < 0.001) during treatment but returned to pre-exercise values within 5 min of recovery in both the SRC and HEALTHY groups. Both the SRC and HEALTHY groups exhibited similar reductions pre- to post-intervention for symptom severity and count (p’s < 0.05), three VOMS items (p’s < 0.05) but not K-D time.
Conclusions
To date, this is the first adolescent RCT to report the acute, systemic effects of aerobic exercise on recently concussed adolescent athletes. The interventions appeared safe in SRC participants, were well-tolerated, and provided brief therapeutic benefit.
Trial registration
Clinicaltrials.gov Identifier NCT03575455.